http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
BridgeBio schedules calls for LGMD2I/R9 trial results and Q3 earnings
-
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
-
BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
BridgeBio reports positive encaleret results for hypoparathyroidism
-
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
-
BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET
-
BridgeBio to present encaleret phase 2 data at ASBMR meeting
-
BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism
-
Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension
-
BridgeBio to Participate in September Investor Conferences
-
BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025
-
BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates
-
BridgeBio study finds ADH1 genetic condition underdiagnosed by 80%
-
Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1
-
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
-
BridgeBio Pharma (BBIO) Raises $300 Million Through Partial Capped Monetization of BEYONTTRA European Royalty
-
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
-
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
-
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
-
Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM
-
BridgeBio Pharma Inc. (BBIO): Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
-
Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
BridgeBio Pharma Inc. (BBIO): First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
-
First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study
-
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Fa
-
BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025
-
BridgeBio Reports First Quarter 2025 Financial Results and Business Updates
-
BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM
-
BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
BridgeBio Pharma (BBIO) Reports Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
-
Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM
-
BridgeBio Pharma (BBIO) Announces Beyonttra Approved in Japan to Treat ATTR-CM
-
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
-
BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Session
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
BridgeBio Pharma Inc. (BBIO) appoints Thomas Trimarchi as CFO
-
BridgeBio Announces CFO Succession
-
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
-
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025
-
BridgeBio Pharma Inc. (BBIO) Announces BEYONTTRA Approved by the European Commission to Treat ATTR-CM
-
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
-
BridgeBio Pharma Inc. (BBIO) Announces Commercial Progress, Program Updates, and 2025 Milestones
-
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones
-
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
-
BridgeBio Pharma's (BBIO) Acoramidis Receives Positive CHMP Opinion
